News J&J cuts $3.3bn deal to buy eye drug developer Ollin Johnson & Johnson has agreed to buy Texas biotech Ollin Biosciences for $2.2bn upfront, adding a keenly anticipated therapy for ophthalmic disorders.
News Lilly strikes again, buying Calytrix in $1.5bn deal Eli Lilly has added yet another name to its list of M&A deals this year after agreeing to buy blood disorder specialist Calytrix Bio for up to $1.5bn.
News China overtakes Europe in healthcare investing sentiment China has overtaken Europe as the preferred location for healthcare investing, according to Jefferies' Healthcare Temperature Check report.
News AZ boosts vaccine capabilities with Omniose buy AstraZeneca has bought a US biotech developing polysaccharide conjugate vaccines for bacterial infections, Omniose, after a three-year partnership.
Market Access Biotech's next growth cycle: Renewed confidence comes with c... Renewed confidence across biopharma is welcome and long overdue after a prolonged period of constraint. But confidence alone is not enough.
News argenx agrees Unnatural takeover deal worth up to $1.15bn argenx has agreed its second acquisition of the year, buying macrocyclic peptide drug developer Unnatural Products for $550m upfront.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.